Don't Rely on Omega-3s for Cardiovascular Benefits

January 2021

Do omega-3 fatty acid supplements reduce CV risk?

Mounting evidence suggests they don't...despite prior evidence with Rx Vascepa (icosapent ethyl), a form of EPA (eicosapentaenoic acid).

Vascepa 2 g BID is approved to reduce CV risk in some high-risk patients with moderately elevated triglycerides despite statins.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote